ATLANTA, Dec. 10, 2007 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the development of new, potentially improved, interferon-alpha-2b (IFNalpha2b) molecules using the Company's proprietary Dock-and-Lock method (DNL). The preclinical results were presented at the 49th annual meeting of ASH in Atlanta, GA.
